Janssen Labs-based Arcturus gets $1.3M boost for RNAi delivery tech

Arcturus Therapeutics, an RNA interference tech company based out of Johnson & Johnson's ($JNJ) and Janssen Pharmaceutical's Janssen Labs, pulled in $1.3 million in a seed funding round from private investors in the U.S. and Canada. The San Diego company, founded in 2013, specializes in nanoparticle delivery technology that uses RNAi drugs to treat rare diseases. The founders, Joseph Payne and Pad Chivukula, who have worked on a novel RNAi treatment for fibrosis, have also created delivery platforms for drugs by DuPont, Merck ($MRK), Bristol-Myers Squibb ($BMY), Kalypsys and Nitto Denko. Release